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Abstract
Objective: Few studies have been published on health care utilization in Crohn's disease and the
influence of psychological treatment on high utilizers.
Methods: The present sub study of a prospective multi center investigation conducted in 87 of
488 consecutive Crohn's disease (CD) patients was designed to investigate the influence of the
course of Crohn's disease on health care utilization (hospital days (HD) and sick leave days (SLD)
collected by German insurance companies) and to examine the conditions of high-utilizing patients.
Predictors of health care utilization should be selected. Based on a standardized somatic treatment,
high health care utilizing patients of the psychotherapy and control groups should be compared
before and after a one-year treatment.
Results:  Multivariate regression analysis identified disease activity at randomization as an
important predictor of the clinical course (r2 = 0.28, p < 0.01). Health care utilization correlated
with duration of disease (p < 0.04), but the model was not significant (r2 = 0.15, p = 0.09). The
patients' level of anxiety, depression and lack of control at randomization predicted their health-
related quality of life at the end of the study (r2 = 0.51, p < 0.00001). Interestingly, steroid intake
and depression (t1) predicted the combined outcome measure (clinical course, HRQL, health care
utilization) of Crohn's disease at the end of the study (r2 = 0.22, p < 0.001).
Among high utilizers, a significantly greater drop in HD (p < 0.03) and in mean in SLD were found
in the treatment compared to the control group.
Conclusion: The course of Crohn's disease is influenced by psychological as well as somatic
factors; especially depression seems important here. A significant drop of health care utilization
demonstrates the benefit of psychological treatment in the subgroup of high-utilizing CD patients.
Further studies are needed to replicate the findings of the clinical outcome in this CD subgroup.
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Introduction
Thought to influence perceived health in inflammatory
bowel disease (IBD), patients' care-seeking behavior has
aroused increasing medical and economic interest, espe-
cially since high users of medical care have turned out to
be a serious therapeutic problem [1]. Due to the chronic
course of their disease with frequent relapses, IBD patients
tend to have more medical care utilization (doctor visits
and hospital days per year) than patients with other gas-
trointestinal diseases [2]. Physical conditions as well as
psychosocial factors are thought to influence the health
status perception of IBD patients and thus also their med-
ical care utilization [4]. The structure of the health care
system in a region or country may also affect medical
health care utilization.
Due to its chronicity, Crohn's disease (CD) not only leads
to physical complaints but also causes many patients to
develop psychological symptoms [5-10] that may influ-
ence their care-seeking behavior. Physical complaints and
psychological factors like coping style may also influences
the health-related quality of life in CD patients [11-14].
There is evidence that psychosocial factors accelerate the
progression of Crohn's disease [15,16], and the individual
health status of CD patients seems to be more closely
related to psychological factors than to somatic ones [4].
The medically defined severity of illness failed to correlate
significantly with variables of health care utilization in
Crohn's disease patients [17].
This paper aims at reevaluating these findings using data
from a previously reported randomized trial, which have
focused on the somatic course of disease [18] and on psy-
chological outcome [19]: it investigates whether factors
relating to the bio psychosocial situation of Crohn's dis-
ease patients correlate with their health care utilization
and whether high health care utilizers benefit from receiv-
ing psychological treatment in combination with stand-
ardized medical therapy [19]. Psychotherapeutic
interventions and educational programs have been posi-
tively assessed for their effectiveness in controlled studies
with both good [20-23] and discouraging results [24,25],
but few controlled studies have been conducted on health
care utilization in Crohn's disease [26,27].
We investigated the following hypotheses:
1. Psychological and clinical factors predict health care
utilization, the somatic course of disease and the health-
related quality of life in CD patients.
2. Psychological treatment reduces health care utilization
in high-utilizing CD patients.
Methods
Patients
Recruitment and screening procedure
During the two-year recruitment period, all consecutive
CD patients from the four participating centers were doc-
umented by recording their anamnestic and underlying
somatic clinical data. The criteria for inclusion in the
study were: Confirmed diagnosis, age between 18 and 55
years, at least one active disease episode (defined as
requiring drug treatment) in the last two years, informed
consent to participate and to be randomized in a psycho-
therapy or non-psychotherapy group. The exclusion crite-
ria were: psychotherapy or resection for Crohn's disease
within the last two years and no further relapse thereafter,
ongoing immunosuppressive therapy or resection in the
near future, and colostomy or ileostomy.
Due to the restrictive inclusion and/or exclusion criteria,
only 108 of 488 patients were randomized in the "PICD"
study: 37 were randomized to the control group and 71 to
the psychotherapy group. The largest group of non-partic-
ipants comprised patients without any relapse in the two
years prior to the basic documentation. Comparison of
the included and excluded patients disclosed no signifi-
cant differences in the distribution of sex, involvement
pattern, or disease duration. As the inclusion/exclusion
criteria indicate, the participants were on average younger
than the non participants, and fewer of them had under-
gone previous resections [18].
Dropouts due to non-fulfillment of the health care utilization criteria
twenty-nine of the 108 patients (26.9%) who met the
inclusion and exclusion criteria could not be evaluated for
health care utilization. They failed to obtain the data from
the German insurance companies within the collecting
period. In further ten patients more then 10% missing
data caused exclusion from the study. The patients who
dropped out were on average younger, and fewer of them
had undergone previous resection. Comparison with the
eligible patients revealed no differences in the distribution
of the involvement pattern, sex, or disease activity at the
time of randomization.
To carry out the following evaluation (conduct the regres-
sion analysis and calculate effects in high-utilizing
patients), we took the 69 randomized CD patients and
completed in 9 other randomized patients the missing
values in the data sets by means. 9 patients of 380 CD
patients were also included. In this study they had pre-
ferred psychotherapy and were therefore not randomized,
but they received the same psychological treatment and
took part in all examinations of the study.
Patients were clinically examined at baseline and every
three months during the two years of the study. Psycho-BioPsychoSocial Medicine 2008, 2:18 http://www.bpsmedicine.com/content/2/1/18
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logical examinations took place at baseline and after 12,
18 and 24 months. The same standardized drug treatment
was provided in both groups (see below). All patients in
the intervention group were entered into a psychological
treatment program (see below). Patients in the control
group received only the eight control examinations. The
study was approved by the local ethics committee.
Assessment of health care utilization
Data on hospital days (HD, n = 87) and sick leave days
(SLD, n = 56) were collected for four years from the differ-
ent German health insurance companies with the
informed consent of the patients (SLD data were not avail-
able for housewives, students or unemployed patients).
We were thus able to include data from two years of health
outcome before randomization, one year after randomi-
zation during psychological treatment, and one year of
follow-up. Analyses of costs (drugs, doctor visits, etc.)
were planned but not performed due to insufficient data
sets.
High utilizers (HU) of health care were characterized as
follows: patients above the median HD during the two-
year study period (n = 41; 28 in the psychotherapy group
and 13 in the control group). The most important param-
eters like age, gender, prior resections and active disease at
randomization were evenly balanced between the two
treatment groups (Table 1). The same holds true for the
socio demographic data: the HU treatment and HU con-
trol group did not differ in their family status, partnership,
children, or education level in this sub analysis of a non-
randomized sample.
Gastroenterological Assessment
Once included in the study, patients were subjected to the
following examinations: complete history, clinical and
laboratory examinations, colonoscopy, esophagogas-
troduodenoscopy, X-ray of the small intestine, and CDAI
calculations [28]. The CDAI was also recorded during all
follow-up examinations, and it was used to decide what
drug treatment was necessary. Each patient's course was
documented for two years. Somatic data were recorded
every three months during remission and once a week
during acute attacks.
Psychosocial Assessment
The patients' psychosocial status was determined [18] on
the basis of their depression self-ratings (Beck's Depres-
sion Inventory: BDI [29]), trait anxiety (STAI-X2 [30]),
health-related quality of life (HRQL, 31), and coping
behavior (CQ [32]).
Table 1: Health care utilization – patients studied and influencing factors
Health care utilization study High-utilizing CD Patients (n = 41)
total (n = 87) Psychotherapy group (n = 28) Control group (n = 13) p
n% n % n %
Male 33 37.9 15 37.5 13 54.2 n. s.
female 54 62.1 25 62.5 11 45.8
age (years) < 30 46 52.9 18 45 15 62.5 n. s.
< 30 41 47.1 22 55 9 37.5
previous no 60 69 30 75 15 62.5 n. s.
resection yes 27 31 10 25 9 37.5
episode no 54 62.1 14 35 10 41.7 n. s.
yes 33 37.9 26 65 14 58.3
involvement pattern
only small intestine 12 14.9 6 15 4 16.7 n.s.
only large intestine 11 12.6 9 22.5 1 4.2
small and large intestine 63 72.4 25 62.5 19 79.2
msm s m s
disease duration (months) 64.3 62.8 65.4 67.7 64.4 44.0 n. s.
Crohn's disease activity index (Best) 153.7 98.1 143.4 93.4 168.3 98.7 n. s.BioPsychoSocial Medicine 2008, 2:18 http://www.bpsmedicine.com/content/2/1/18
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Combined measurement of health care utilization, the 
HRQL, and the somatic course of disease
We defined three outcome measurements (each on a 6-
step evaluation scale from higher to lower values) to ana-
lyze clinically meaningful fields of the disease:
Health care utilization
six groups with utilization differences in HD and SLD dur-
ing the two-year study period: 0 HD and 0 SLD = 0 (n =
18); 0 HD, 1–40 SLD = 1 (n = 18); 0 HD, >40 SLD = 2 (n
= 9); 1–14 HD, 8–71 SLD = 3 (n = 9); 15–30 HD, 88–184
SLD = 4 (n = 4); >30 HD, 121–331 SLD = 5 (n = 6).
Health-related quality of life
six groups with combined mean values in the HRQL sum
score [26]: six (t 18: m 60.4, sd 20.5) and twelve months
(t 24: m 66.4, sd 20.3) after psychotherapeutic treatment.
Somatic course of Crohn's disease
six different groups after sub ranking the main outcome
group (blinded estimation of each case): episode-free
course = 0; course with episodes and response to corticoid
therapy = 1–3; course with episodes and failure of stand-
ard therapy with corticoids = 4; course with surgery for
intractable inflammatory activity = 5 [19].
This enabled a combined outcome measurement of three
areas representing biological, psychological and health
care aspects of the disease.
Treatment
Drug treatment
Based on the study protocol of the European Cooperative
Crohn's Disease Study/ECCDS [33], we used a fixed dos-
ing scheme for administering corticosteroids during acute
episodes: 60 mg of prednisolone daily as the initial dose
was followed by weekly reductions to 40 mg, 30 mg, 25
mg, 20 mg, and 15 mg. Patients were given 10 mg/day
from week 7 to 19 and 10 mg every other day from week
20 to 28. Sulfasalazine was allowed in patients with
colonic Crohn's disease, 5-ASA in all cases. If remission or
a significant reduction of CDAI [28] was not achieved
after 6 weeks of drug treatment, the same scheme was
repeated, beginning with 60 mg of prednisolone. No drug
treatment was given during remission of the disease.
Psychological treatment
For the intervention group, all participating centers pro-
vided basic short-term psychodynamic psychotherapy (20
hours) and a relaxation treatment program (10 autogenic
training sessions). The total length of psychotherapy was
not to exceed one year. The mean duration was 47.0 weeks
(SD 31.2) for therapy across the four study centers, 26.2
weeks (SD 20.5) for the total number of verbal therapy
sessions, and 17.6 weeks (SD 10.4) for the mean number
of relaxation therapy sessions.
The aim of verbal psychotherapy was to provide health
education and health-promoting behaviors, to give
patients greater responsibility and control over their treat-
ment, and to improve their coping skills and adjustment
to the disease. Another aim was to alleviate possible dis-
ease-related psychological distress and maladaptive inter-
personal patterns. Although no manual was used, the
psychotherapy provided was based on the principles of
psychodynamic psychotherapy and was standardized
within the study centers [18].
Statistical analysis
Calculation of correlations (Spearman) and multivariate
regression analysis were done with the whole sample of
87 CD patients to detect factors influencing health care
utilization.
Therapeutic results were analyzed only in high-utilizing
Crohn's disease patients. Patient selection and the homo-
geneity of the two therapy groups were evaluated with
respect to important somatic and psychosocial parame-
ters. The two HU treatment groups were compared with
regard to their overall HD and SLD scores assessed two
years before randomization (divided by two) and at the
one-year follow-up after psychological treatment.
All group comparisons were performed with the Mann-
Whitney U-test or the t-test for continuous or ordinal var-
iables and Fisher's exact test for categorial variables. The
alpha errors of the tests were adjusted according to Bon-
ferroni-Holm in order ensure an overall significance level
of α = 0.05. All calculations were performed using the Sta-
tistical Analysis System (SAS, SAS Institute, Cary, NC,
USA).
Results
Subjects in the high-utilizer study (n = 87) had a mean age
of 31.3 years (sd 30.0) and showed female preponderance
(62.1%). An acute episode of disease activity occurred in
37.9% of these patients at the beginning of the study, and
31 % had a history of bowel resections. Local findings
involved the ileum and colon in 72.4% of the patients, the
colon in 12.6%, and the ileum in 14.9% (Table 1).
On the BDI depression scale, this sample had a mean
score of 11.5 (sd 8.1), which is below the range of mild
depression. The mean STAI anxiety value was 41.5 (sd
10.7) which ranges between normal controls and a clini-
cal population. The same was also true for the HRQL val-
ues (m 70.0, sd 20.0).BioPsychoSocial Medicine 2008, 2:18 http://www.bpsmedicine.com/content/2/1/18
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According to data collected from the German insurance
companies, the examined 87 subjects had 24.4 HD (sd
32.3) and 92.6 SLD (sd 83.7) at the end of the two-year
study period. It was interesting to note that the health care
utilization (HCU) data collected from the patients every
three months in a personal examination did not correlate
very well with the data obtained from the insurance com-
panies (IC). The IC data for HD correlated in only 62.5%
before and 63.3% after randomization. The correlation
for SLD was 54.5% before and 57.6% after randomiza-
tion.
In a first step, we calculated both HD and SLD with
important anamnestic and psychological variables: gen-
der (the female gender was a strong predictor for the
number of HD before (.32, p < 0.05) and after randomi-
zation (.25, p < 0.05)), the Crohn's activity index (CDAI,
.35, p < 0.05), and the scale of cognitive diversity (CQ
scale 1; -.32, p < 0.05) correlated with the number of SLD
before randomization.
Calculation of a combined outcome measure in health 
care utilization, the clinical course, and the HRQL
To combine different biological, psychological and HCU
aspects in the course of disease, we created a common
measurement of HCU with HD and SLD during the two-
year study period. Using this instrument to rate outcome
on a scale of 0 – 5, the course of disease within the two-
year study period was 3.26 (sd 1.62) for health care utili-
zation, 2.90 (sd 1.47) for the HRQL, and 2.39 (sd 1.57)
for the clinical course of the disease. The sum score was
8.25 (sd 3.27)
The three outcome measurements in the course of the
study did not show a very high correlation (significant
only for the clinical course and the HRQL at .30, p < 0.05).
However, we found correlations with interesting psycho-
logical and clinical factors in each of the three dimen-
sions. In the univariate analysis, the combined health care
utilization measure correlated most closely with the BDI
depression scale, the steroid intake, and the number of
SLD at t 1. The disease activity (CDAI), steroid intake and
depression at t1 predicted the somatic course of disease.
The HRQL showed the highest correlation with anxiety,
depression, lack of behavior control, SLD in the years
before randomization, and the duration of disease (Table
2a).
In separate multiple regression analyses of the somatic,
psychological and health care status, the disease duration
was a significant predictor of health care utilization (com-
bined measurement of HD and SLD), but the model was
not significant (r2 = 0.15, p = 0.09).
Multivariate regression analysis identified disease activity
at randomization as an important predictor of the clinical
course (r2 = 0.28, p < 0.01). The patient's level of anxiety
and lack of control at randomization predicted the health-
related quality of life at the end of the study (r2 = 0.51, p
< 0.00001).
In a summarized regression analysis of all the above-men-
tioned parameters, steroid intake and depression (t1)
proved to be highly significant predictors of the combined
outcome measure (clinical course, HRQL, health care uti-
lization) of Crohn's disease in the long run (r2 = 0.22, p <
0.001, Table 2b).
Effect of psychosomatic treatment in high utilizers
We created a group of 41 high-utilizing patients (HU)
above the 50th percentile of HD by median split (more
than 17 HD within the two-year study period) and a
group of low-utilizing patients (LU, <17 HD). The two
groups did not differ significantly variables of influence
like age, earlier resections or current episodes. However,
the high utilizers showed a female preponderance (p <
0.05). Hospital days were 44.4 (sd 36.0) for HU and 4.9
(sd 6.26) for LU. Sick leave days were 129.3 (sd 89.1) for
HU (n = 34) and 53.6 (sd 56.5) for LU (n = 32).
Calculating the treatment study results in 41 high-utiliz-
ing patients (28 in the psychotherapy group and 13 in the
control group, Table 1) revealed a significant difference in
HD (p < 0.0001) between the treatment group (24.2 (sd
20.8) to 5.7 (sd 13.4)) and controls (17.6 (sd 7.6) to 19.9
(sd 32.9)) in the year before randomization compared to
the year of follow-up. The mean SLD decreased in the
treatment group (67.9 (sd 40.0) to 57.8 (sd 81.4)) and
increased in the control group (55.5 (sd 57.2) to 123.9 (sd
145.6)), but this was not significant, since the calculation
involved only the reduced number of employed patients
(19 therapy group; 8 control group, Fig. 1). Interestingly,
the adherence of patients to the general practitioners did
not change in the course of time, the number of visited
doctors per year remaining nearly the same in both
groups.
Discussion
The present trial evaluated the influence of somatic and
psychological factors on health care utilization in the
course of Crohn's disease (CD) and the effect of a psycho-
logical intervention on high-utilizing CD patients. The
somatic and psychosocial course of CD patients submit-
ted to a psychological intervention has already been
described [18,19]. Eighty-seven of 488 consecutive
patients in the four participating centers were included in
the protocol of the sub study evaluated here. Due to an
ambitious study protocol, 75% of the screened patients
were excluded [19]. High patient adherence was requiredBioPsychoSocial Medicine 2008, 2:18 http://www.bpsmedicine.com/content/2/1/18
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in view of the many clinical and psychological examina-
tions as well as the collection of health care data from Ger-
man insurance companies. These patients were selected
for showing high disease activity without requiring a sur-
gical intervention. Moreover, there was a relatively high
dropout rate in collecting the bio psychological and
health care utilization data. Comparing the epidemiolog-
ical data of the patients included with those of larger
cohorts [34,35] shows a slightly higher mean age. This can
be explained by the fact that our study only included
patients over the age of 18. There were more women than
men in our study, while the literature generally reports a
balanced gender ratio [36]. The disease distribution along
the intestinal tract in our study population is comparable
to that reported in other studies [36,37]. The study proto-
col excluded patients seeking psychological treatment for
psychosocial problems as well as those exhibiting a severe
somatic course with psychological distress. Psychological
data thus showed few psychological symptoms in our
study patients. A low baseline level of psychosocial dis-
tress in IBD patients was also confirmed by Drossman et
al. [5]. This is consistent with data indicating that, despite
their symptoms, patients with IBD perceive their health-
related quality of life as being quite good [10].
With the aim to present an appropriate outcome measure,
it was very important to describe the somatic course of the
disease over a two-year period. We used the ECCDS pro-
tocol [34] to develop a ranking scheme ranging from the
best to the worst clinical course. This enabled very careful
evaluation of the somatic outcome criterion in 87
patients.
Table 2: Predictors of Crohn's disease and combined psychosomatic outcome measure in 87 CD patients within two years
a) Univariate correlation
outcome of Crohn's disease (worse)
predictors (t0) health care utilization HRQL clinical course sum score
CDAI •145 •040 •470*** •324*
steroid intake •291* •025 •352** •306*
disease duration •129 •226* •01 •059
sick leave at randomization •288* •021 •315* •354**
depression (BDI) .587*** •306* •384** •248
anxiety (STAI) •101 •655*** •255 •349*
behavior control (FK 2) -•162 -•230* -•069 -•043
b) Regression analysis
Health care utilization (HCU, high)
Model: r2 = 0.15 F = 2.32 p = 0.09
β Tp
1. Disease duration 0.92 2.1 0.04
Health-related quality of life (HRQL, low)
Model: r2 = 0.51 F = 15.5 p = 0.00001
β Tp
1. Anxiety (STAI) -0.45 -3.9 0.0003
2. Behavior control (FK 2) 0.22 2.0 0.05
Clinical course of disease (CCD, worse)
Model: r2 = 0.28 F = 6.16 p = 0.006
β Tp
1. CDAI (t0) -0.43 -2.9 0.007
HR sum score: (HCU, HRQL, CCD)
Model: r2 = 0.22 F = 7.9 p = 0.0009
β Tp
1. steroid intake 0.31 2.6 0.01
2. depression (BDI) 0.30 2.5 0.02
* p < 0.05 ** p < 0.01 *** p < 0.001BioPsychoSocial Medicine 2008, 2:18 http://www.bpsmedicine.com/content/2/1/18
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High utilizer with Crohn's disease within three years before, during and after psychotherapy 1a) days in hospital (DH; Mann  Whitney test p < 0.05) and 1b) sick leave days (SLD; Mann Whitney test p < 0.1) Figure 1
High utilizer with Crohn's disease within three years before, during and after psychotherapy 1a) days in hospi-
tal (DH; Mann Whitney test p < 0.05) and 1b) sick leave days (SLD; Mann Whitney test p < 0.1). SLD data were 
not available for house wives, students and unemployed patients. So the control group (n = 9) and the psychotherapy group (n 
= 22) showed a lower number of patients.BioPsychoSocial Medicine 2008, 2:18 http://www.bpsmedicine.com/content/2/1/18
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After a six- and twelve-month follow-up, we also assessed
the HRQL by a self-rating questionnaire and a well known
psychological outcome measurement.
This study was the first to collect CD health care data from
German insurance companies (with surprising results
regarding the validity of clinical HCU data collection). We
are thus able to present a validated third (HCU) outcome
variable. We found a high rate of care-seeking behavior in
our patient population. It seemed very helpful in this con-
text that patients were also checked very carefully with
regard to their somatic and psychological course. How-
ever, the longer collecting time and complex analyses of
data are the cause of this study being completed much
later than our first publication.
The predictor analyses according to the amount of health
care utilization in the study population (combined meas-
ure of HD and SLD) detected steroid intake, sick leave sta-
tus, depression, and gender as significant variables of the
univariate analysis. This is in agreement with other studies
[5,7,14,38]. However, all variables except disease dura-
tion failed to reach statistical significance in the multiple
regression analysis, and the statistical model with r2 = 0.15
was not significant. The findings in this analysis thus
remain weak and unconvincing.
The HRQL in the course of disease could be predicted by
psychological, anamnestic and HCU variables (anxiety,
depression and coping skills as well as the disease dura-
tion and the number of sick leave days in the two years
before examination). This is in agreement with other stud-
ies [11-15,39]. Anxiety and coping skills could be
included in a highly significant statistical model with r2 =
0.51.
Interestingly, the somatic course of disease could be pre-
dicted by variables of acute inflammation (CDAI, steroid
intake), psychological indicators (depression), and varia-
bles of health care utilization (SLD). Regression analysis
identified the CDAI as the only significant variable in a
significant model (r2 = 0.28).
By combining the three outcome measurements of health
care utilization and the HRLQ as well as the clinical
course, we identified depression and steroid intake at ran-
domization as highly significant predictors of the course
of illness over two years in a significant statistical model
(r2  = 0.22). Disease activity and depression are well-
known predictors of the course in Crohn's disease patients
[7,11,14].
The carefully selected outcome variables enabled us to
examine the effectiveness of a psychological treatment in
the high-utilizing sub sample. Since there is only a poor
response concerning the somatic course of disease to psy-
chological treatment in CD patients it seems important to
analyze sub populations. The definition of high utilizers
in this study were done by median split of the medical
health care data. Whether this is useful in general future
studies have to demonstrate. It seems interesting that
health care utilization in terms of hospital days and sick
leave days was much higher in this CD study group than
in other studies [2,5,24,25]. Here we have to take into
consideration the health care situation in Germany, in the
study cities and their surrounding regions. However, the
fact that women had much higher HD and SLD values
than men suggests that factors beside the somatic course
of illness are important here.
Forty-one high-utilizing patients showed significant dif-
ferences in the course of HD and SLD (difference between
the value one year before randomization and at the one-
year follow-up) with an advantage for the intervention
group. Thus the present study was able to demonstrate the
effectiveness of psychological treatment in reducing the
health care utilization of these high-utilizing Crohn's dis-
ease patients. This seems interesting, since the rand-
omized study failed to support significant somatic or
psychological improvement following the psychological
intervention [18,19] but showed a significant decrease of
HD in the treatment group [40]. It is noteworthy that the
results of the randomized study also hold true for high-
utilizing Crohn's disease patients [26]. We were thus able
to show that a psychological treatment was benefitial for
this CD subgroup of high and cost-intensive health care
utilizers without worsening their adherence to the medi-
cal regimen. The psychological focus in treating a CD sub-
group of patients to change their psychological status and
health care utilization is new and has thus far only been
used in this sample of CD patients. Moderating factors
seem to be the patients' more effective disease self-man-
agement, better adherence and more security in illness
behavior during disease crises. Depressive symptoms
decreased in CD patients, who had formerly high levels of
depression [19]. A longer waiting time before (or neglect
of) bowel surgery may be another reason. Greater skill in
coping with the illness or with stressful life events may
lead to fewer psychic symptoms [18-20] and a better
HRQL [1,14,15] as well as risk factors like dietary habits
or smoking may influence the possibility of going to the
hospital or going to work [5]. These aspects could only be
partly detected by our psychological measurement (18),
but we assume they are meaningful for the change in
health care utilization in the psychological treatment
group [26].
Several aspects and limitations should be taken into
account when interpreting the present results. The many
exclusion criteria in the original trial [19] led to an exam-BioPsychoSocial Medicine 2008, 2:18 http://www.bpsmedicine.com/content/2/1/18
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ination rate of 87 in this sub study with 488 screened CD
patients from specialized GI university medical centers. 87
of these patients included in this health utilization study
came from a randomized sample [69], an additional sam-
ple wanted psychotherapy [9] and a third group had a
high rate of missing data [9] but could be accepted in this
analysis. Patients with surgery or those without relapses
within the two years before the trial were excluded. Few
patients with psychic disturbances like depression, anxiety
or a low HRQL were included in the study.
The treatment results relate to a high-level health care
population without severe psychiatric co morbidity and
were obtained over an observation period of four years. It
is possible that the treatment effect on health care utiliza-
tion would be greater if we examined CD populations
with higher psychiatric co-morbidity.
The type and dose of applied psychological treatment in
this study should also be taken into consideration: It
seems helpful to spend a minimum amount of time com-
municating with CD patients [41] and to provide infor-
mation and offer education programs [21,22], but an
intensive psychological treatment program [24,25,34]
that focuses on changing coping skills and illness behav-
ior [15] may intensify common treatment effects in high-
utilizing CD patients.
Conclusion
In summary, health care utilization proved to correlate
closely with the somatic course as well as with psychic and
anamnestic variables of the disease. Inflammatory activity
and depression were important predictors of the com-
bined biological, psychological and health care utilization
endpoint of Crohn's disease. Thus it seems useful to
describe a subgroup of high-utilizing Crohn's disease
patients. Interestingly, they proved likely to benefit from
psychological treatment. Variables of health care utiliza-
tion should be included in future therapy studies, espe-
cially those examining high-utilizing Crohn's disease
patients.
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